Mission Statement, Vision, & Core Values (2024) of Tyra Biosciences, Inc. (TYRA)

Mission Statement, Vision, & Core Values (2024) of Tyra Biosciences, Inc. (TYRA)

US | Healthcare | Biotechnology | NASDAQ

Tyra Biosciences, Inc. (TYRA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Tyra Biosciences, Inc. (TYRA)

General Summary of Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. is a precision oncology company focused on developing targeted therapies for genomically defined cancers. Founded in 2017 and headquartered in South San Francisco, California.

Company Products and Services

Primary focus areas include:

  • Precision oncology therapeutics
  • Genomic cancer treatment development
  • Targeted therapy research

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $18.4 million
Net Loss ($93.5 million)
Research & Development Expenses $71.2 million
Cash and Cash Equivalents $285.6 million

Key Pipeline Information

Current clinical-stage programs:

  • TYRA-1501: FGFR-selective inhibitor
  • TYRA-2510: CDK4/6 inhibitor

Industry Leadership Indicators

Key Competitive Advantages:

  • Proprietary precision oncology platform
  • Advanced genomic targeting technologies
  • Focused clinical development strategy

Stock Performance

Stock Symbol NASDAQ: TYRA
IPO Date July 22, 2021
Current Share Price (as of 2024) $7.23



Mission Statement of Tyra Biosciences, Inc. (TYRA)

Mission Statement Overview

Tyra Biosciences, Inc. (TYRA) mission statement focuses on precision oncology and targeted cancer therapies.

Mission Statement Components

Component Specific Details
Research Focus Developing targeted therapies for genomically defined cancers
Scientific Approach Precision oncology targeting specific genetic mutations
Patient Impact Improving cancer treatment outcomes through personalized medicine

Research and Development Strategy

Tyra Biosciences has $94.2 million in research and development expenses as of Q3 2023.

  • Primary research platforms targeting FGFR and EGFR genetic alterations
  • Developing small molecule inhibitors for cancer treatment
  • Focus on precision oncology therapeutic approaches

Key Scientific Priorities

Priority Area Current Investment
FGFR Inhibitor Development $42.7 million allocated in 2023
Genomic Cancer Research 37% of total R&D budget

Clinical Pipeline Metrics

Current clinical pipeline includes 3 active therapeutic programs targeting specific genetic mutations.

  • TYRA-1501: Phase 1/2 clinical trial for FGFR-altered cancers
  • Total active clinical trials: 2 ongoing studies
  • Projected patient enrollment: 120 patients across current trials

Financial Commitment to Mission

Tyra Biosciences reported $156.3 million in total funding as of December 2023.

Funding Source Amount
Venture Capital $98.6 million
Research Grants $22.4 million



Vision Statement of Tyra Biosciences, Inc. (TYRA)

Vision Statement Components of Tyra Biosciences, Inc. (TYRA)

Precision Oncology Focus

Tyra Biosciences aims to develop targeted therapies for patients with genomically defined cancers. As of Q4 2023, the company's research pipeline targets specific genetic mutations in cancer treatment.

Research Area Target Mutation Development Stage
FGFR Inhibition FGFR1/2/3 Alterations Phase 2 Clinical Trials
Innovation in Molecular Targeted Therapies

The company concentrates on developing small molecule inhibitors addressing complex genetic alterations in cancer.

  • Research investment: $42.3 million in 2023
  • Active clinical programs: 3 primary molecular targeting initiatives
  • Patent portfolio: 17 granted patents
Strategic Therapeutic Development

Tyra Biosciences prioritizes developing therapies for patient populations with limited treatment options.

Therapeutic Area Patient Population Unmet Medical Need
Solid Tumors Genomically Defined Cancers High Molecular Complexity
Scientific Collaboration and Advancement

Tyra collaborates with leading research institutions to accelerate therapeutic discovery.

  • Academic partnerships: 5 active research collaborations
  • Scientific advisory board: 7 distinguished oncology experts



Core Values of Tyra Biosciences, Inc. (TYRA)

Core Values of Tyra Biosciences, Inc. (TYRA)

Innovation and Scientific Excellence

Tyra Biosciences demonstrates commitment to innovation through substantial R&D investments. As of Q4 2023, the company allocated $42.3 million to research and development, representing 68% of total operating expenses.

R&D Metric 2023 Value
Total R&D Expenditure $42.3 million
R&D as % of Operating Expenses 68%
Active Research Programs 7 distinct oncology programs

Patient-Centric Approach

Tyra Biosciences prioritizes patient outcomes through targeted therapeutic development.

  • Focused on precision oncology targeting specific genetic mutations
  • Clinical trials addressing unmet medical needs
  • Personalized treatment strategy development

Collaborative Scientific Ecosystem

The company maintains strategic partnerships with research institutions.

Partnership Type Number of Collaborations
Academic Research Partnerships 4
Pharmaceutical Collaborations 2
Total Research Collaborations 6

Ethical and Transparent Operations

Tyra Biosciences maintains rigorous compliance standards.

  • 100% compliance with FDA regulatory requirements
  • Comprehensive clinical trial transparency protocols
  • Independent ethics review board engagement

Sustainable Scientific Progress

The company's financial metrics reflect sustainable growth trajectory.

Financial Metric 2023 Value
Cash and Cash Equivalents $218.5 million
Net Loss $87.2 million
Research Pipeline Value Estimated $750 million

DCF model

Tyra Biosciences, Inc. (TYRA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.